Clinical mycophenolic acid monitoring in liver transplant recipients

World Journal of Gastroenterology

Volumn 20, Issue 31, 2014, Pages 10715-10728

  Chen, Hao ^a   Chen, Bing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Liver transplantation; Mycophenolate mofetil; Mycophenolic acid; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

CYCLOSPORIN A; DRUG METABOLITE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; TACROLIMUS;

ACUTE GRAFT REJECTION; AREA UNDER THE CURVE; BACTERIAL INFECTION; BAYES THEOREM; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG GLUCURONIDATION; DRUG MONITORING; FLUORESCENCE; GRAFT INFECTION; GRAFT RECIPIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; KIDNEY FAILURE; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; META ANALYSIS (TOPIC); MYCOSIS; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW (TOPIC); TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET RADIATION; VIRUS INFECTION; ADVERSE EFFECTS; BIOLOGICAL MODEL; BLOOD; DRUG EFFECTS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; PREDICTIVE VALUE; TIME; TREATMENT OUTCOME;

DRUG MONITORING; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84909634392     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i31.10715     Document Type: Review

References (94)

1. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 1996; 28: 925-929 [PMID: 8623466]
2. Shipkova M, Armstrong VW, Wieland E, Niedmann PD, Schütz E, Brenner-Weiss G, Voihsel M, Braun F, Oellerich M. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 1999; 126: 1075-1082 [PMID: 10204993 DOI: 10.1038/sj.bjp.0702399]
3. Budde K, Curtis J, Knoll G, Chan L, Neumayer HH, Seifu Y, Hall M. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004; 4: 237-243 [PMID: 14974945 DOI: 10.1046/j.1600-6143.2003.00321.x]
4. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol 2005; 1: 505-526 [PMID: 16863458 DOI: 10.1517/17425255.1.3.505]
5. Johnston A, Holt DW. Immunosuppressant drugs - the role of therapeutic drug monitoring. Br J Clin Pharmacol 2001; 52 Suppl 1:61S-73S [PMID: 11564054 DOI: 10.1111/j.1365-2125.2001.00365.x]
6. Srinivas TR, Kaplan B, Meier-Kriesche HU. Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother 2003; 4: 2325-2345 [PMID: 14640931 DOI: 10.1517/14656566.4.12.2325]
7. Hoffman-La Roche Ltd., CellCept Prescribing information. Accessed 23/2/2010. Available from: URL: http://www.gene.com/gene/products/information/cellcept/pdf/pi.pdf
8. Shaw LM, Korecka M, Aradhye S, Grossman R, Bayer L, Innes C, Cucciara A, Barker C, Naji A, Nicholls A, Brayman K. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol 2000; 40: 624-633 [PMID: 10868313 DOI: 10.1177/00912700022009260]
9. Oellerich M, Shipkova M, Schütz E, Wieland E, Weber L, Tönshoff B, Armstrong VW. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 2000; 22: 20-26 [PMID: 10688252 DOI: 10.1097/00007691-200002000-00004]
10. Le Meur Y, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S, Etienne I, Westeel PF, Hurault de Ligny B, Rostaing L, Thervet E, Szelag JC, Rérolle JP, Rousseau A, Touchard G, Marquet P. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496-2503 [PMID: 17908276 DOI: 10.1111/j.1600-6143.2007.01983.x]
11. Brunet M, Cirera I, Martorell J, Vidal E, Millán O, Jiménez O, Rojo I, Londoño MC, Rimola A. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation 2006; 81: 541-546 [PMID: 16495801 DOI: 10.1097/01.tp.0000200307.79962.48]
12. Venkataramanan R, Shaw LM. Therapeutic monitoring of mycophenolic acid in liver transplant patients. Liver Transpl 2004; 10: 503-505 [PMID: 15048792 DOI: 10.1002/lt.20125]
13. Cantarovich M, Brown NW, Ensom MH, Jain A, Kuypers DR, Van Gelder T, Tredger JM. Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: a consensus report. Transplant Rev (Orlando) 2011; 25: 65-77 [PMID: 21454066 DOI: 10.1016/j.trre.2010.12.001]
14. Beckebaum S, Armstrong VW, Cicinnati VR, Streit F, Klein CG, Gerken G, Paul A, Oellerich M. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil. Ther Drug Monit 2009; 31: 205-210 [PMID: 19307937 DOI: 10.1097/FTD.0b013e31819743d9]
15. McDiarmid SV. Mycophenolate mofetil in liver transplantation. Clin Transplant 1996; 10: 140-145 [PMID: 8680052]
16. Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, McMaster P, Kalayoglu M, Levy G, Freeman R, Bismuth H, Neuhaus P, Mamelok R, Wang W. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7: 442-450 [PMID: 11349266 DOI: 10.1053/jlts.2001.23356]
17. Goralczyk AD, Bari N, Abu-Ajaj W, Lorf T, Ramadori G, Friede T, Obed A. Calcineurin inhibitor sparing with mycophenolate mofetil in liver transplantion: a systematic review of randomized controlled trials. Am J Transplant 2012; 12: 2601-2607 [PMID: 22813081 DOI: 10.1111/j.1600-6143.2012.04157.x]
18. Ringe B, Braun F, Schütz E, Füzesi L, Lorf T, Canelo R, Oellerich M, Ramadori G. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation 2001; 71: 508-515 [PMID: 11258429 DOI: 10.1097/00007890-200102270-00005]
19. Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000; 47: 215-245 [PMID: 10878291 DOI: 10.1016/S0162-3109(00)00190-9]
20. Klupp J, Bechstein WO, Platz KP, Keck H, Lemmens HP, Knoop M, Langrehr JM, Neuhaus R, Pratschke J, Neuhaus P. Mycophenolate mofetil added to immunosuppression after liver transplantation - first results. Transpl Int 1997; 10: 223-228 [PMID: 9163864 DOI: 10.1111/j.1432-2277.1997.tb00690.x]
21. Eckhoff DE, McGuire BM, Frenette LR, Contreras JL, Hudson SL, Bynon JS. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998; 65: 180-187 [PMID: 9458011 DOI: 10.1097/00007890-199801270-00006]
22. Schlitt HJ, Barkmann A, Böker KH, Schmidt HH, Emmanouilidis N, Rosenau J, Bahr MJ, Tusch G, Manns MP, Nashan B, Klempnauer J. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357: 587-591 [PMID: 11558484 DOI: 10.1016/S0140-6736(00)04055-1]
23. Pageaux GP, Rostaing L, Calmus Y, Duvoux C, Vanlemmens C, Hardgwissen J, Bernard PH, Barbotte E, Vercambre L, Bismuth M, Puche P, Navarro F, Larrey D. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2006; 12: 1755-1760 [PMID: 17133564 DOI: 10.1002/lt.20903]
24. Cicinnati VR, Yu Z, Klein CG, Sotiropoulos GC, Saner F, Malagó M, Frilling A, Gerken G, Broelsch CE, Beckebaum S. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients - assessment of renal and allograft function, cardiovascular risk factors and immune monitoring. Aliment Pharmacol Ther 2007; 26: 1195-1208 [PMID: 17944734 DOI: 10.1111/j.1365-2036.2007.03466.x]
25. Kriss M, Sotil EU, Abecassis M, Welti M, Levitsky J. Mycophenolate mofetil monotherapy in liver transplant recipients. Clin Transplant 2011; 25: E639-E646 [PMID: 22007615 DOI: 10.1111/j.1399-0012.2011.01512.x]
26. Evans HM, McKiernan PJ, Kelly DA. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation 2005; 79: 1575-1580 [PMID: 15940048 DOI: 10.1097/01.TP.0000163504.29054.3F]
27. Aberg F, Jula A, Höckerstedt K, Isoniemi H. Cardiovascular risk profile of patients with acute liver failure after liver transplantation when compared with the general population. Transplantation 2010; 89: 61-68 [PMID: 20061920 DOI: 10.1097/TP.0b013e3181bcd682]
28. Junge G, Neuhaus R, Schewior L, Klupp J, Guckelberger O, Langrehr JM, Tullius S, Neuhaus P. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. Transplant Proc 2005; 37: 1695-1696 [PMID: 15919434 DOI: 10.1016/j.transproceed.2005.03.145]
29. Bilbao I, Castells L, Rojas L, Cancino J, Dopazo C, Castro E, Pou L, Andino R, Margarit C. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients. Int Immunopharmacol 2006; 6: 1977-1983 [PMID: 17161351 DOI: 10.1016/j.intimp.2006.09.022]
30. Gerhardt T, Terjung B, Knipper P, Palmedo H, Woitas RP, Kalff J, Sauerbruch T, Spengler U. Renal impairment after liver transplantation - a pilot trial of calcineurin inhibitorfree vs. calcineurin inhibitor sparing immunosuppression in patients with mildly impaired renal function after liver transplantation. Eur J Med Res 2009; 14: 210-215 [PMID: 19541578 DOI: 10.1186/2047-783X-14-5-210]
31. Hao C, Anwei M, Bing C, Baiyong S, Weixia Z, Chuan S, Erzhen C, Xiaxing D, Weihua Q, Weiping Y, Chenghong P, Hongwei L. Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia. Liver Transpl 2008; 14: 1165-1173 [PMID: 18668650 DOI: 10.1002/lt.21600]
32. Tredger JM, Brown NW, Adams J, Gonde CE, Dhawan A, Rela M, Heaton N. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl 2004; 10: 492-502 [PMID: 15048791 DOI: 10.1002/lt.20124]
33. Pfitzmann R, Klupp J, Langrehr JM, Uhl M, Neuhaus R, Settmacher U, Steinmüller T, Neuhaus P. Mycophenolatemofetil for immunosuppression after liver transplantation: a followup study of 191 patients. Transplantation 2003; 76: 130-136 [PMID: 12865798 DOI: 10.1097/01.TP.0000071522.74885.48]
34. Fairbanks KD, Thuluvath PJ. Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transpl 2004; 10: 1189-1194 [PMID: 15350013 DOI: 10.1002/lt.20210]
35. Moreno JM, Rubio E, Gómez A, Lopez-Monclus J, Herreros A, Revilla J, Navarrete E, Sánchez Turrión V, Jimenez M, Cuervas-Mons V. Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation. Transplant Proc 2003; 35: 1874-1876 [PMID: 12962831 DOI: 10.1016/S0041-1345(03)00643-2]
36. Moreno Planas JM, Cuervas-Mons Martinez V, Rubio Gonzalez E, Gomez Cruz A, Lopez-Monclus J, Sánchez-Turrion V, Lucena Poza JL, Jimenez Garrido M, Millan I. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 2004; 4: 1650-1655 [PMID: 15367220 DOI: 10.1111/j.1600-6143.2004.00556.x]
37. Maes BD, Vanwalleghem J, Kuypers D, Ghoos Y, Rutgeerts PJ, Vanrenterghem YF. Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. Transplantation 1999; 68: 1482-1485 [PMID: 10589943 DOI: 10.1097/00007890-199911270-00009]
38. Xia ZW, Jun CY, Hao C, Bing C, Min SM, Jie XJ. The occurrence of diarrhea not related to the pharmacokinetics of MPA and its metabolites in liver transplant patients. Eur J Clin Pharmacol 2010; 66: 671-679 [PMID: 20473489 DOI: 10.1007/s00228-010-0833-2]
39. Elbarbry FA, Shoker AS. Liquid chromatographic determination of mycophenolic acid and its metabolites in human kidney transplant plasma: pharmacokinetic application. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 859: 276-281 [PMID: 17964230 DOI: 10.1016/j.jchromb.2007.09.036]
40. Patel CG, Akhlaghi F. High-performance liquid chromatography method for the determination of mycophenolic acid and its acyl and phenol glucuronide metabolites in human plasma. Ther Drug Monit 2006; 28: 116-122 [PMID: 16418705 DOI: 10.1097/01.ftd.0000177664.96726.56]
41. Chen B, Zhang WX, Yu ZC, Cai WM. Determination of Mycophenolic Acid (MPA) and Its Acyl and Phenol Glucuronide Metabolits Simultaneously in Human Plasma by a Simplified HPLC Method. Analytical Letter 2007; 40: 2465-2475 [DOI: 10.1080/00032710701583466]
42. Shipkova M, Schütz E, Armstrong VW, Niedmann PD, Oellerich M, Wieland E. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem 2000; 46: 365-372 [PMID: 10702523]
43. Khoschsorur G, Erwa W. Liquid chromatographic method for simultaneous determination of mycophenolic acid and its phenol- and acylglucuronide metabolites in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 799: 355-360 [PMID: 14670756 DOI: 10.1016/j.jchromb.2003.10.074]
44. Brandhorst G, Streit F, Goetze S, Oellerich M, Armstrong VW. Quantification by liquid chromatography tandem mass spectrometry of mycophenolic acid and its phenol and acyl glucuronide metabolites. Clin Chem 2006; 52: 1962-1964 [PMID: 16931568 DOI: 10.1373/clinchem.2006.074336]
45. Klepacki J, Klawitter J, Bendrick-Peart J, Schniedewind B, Heischmann S, Shokati T, Christians U, Klawitter J. A highthroughput U-HPLC-MS/MS assay for the quantification of mycophenolic acid and its major metabolites mycophenolic acid glucuronide and mycophenolic acid acyl-glucuronide in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 883-884: 113-119 [PMID: 21839692 DOI: 10.1016/j.jchromb.2011.07.021]
46. Aresta A, Palmisano F, Zambonin CG, Schena P, Grandaliano G. Simultaneous determination of free mycophenolic acid and its glucuronide in serum of patients under mycophenolate mophetil therapy by ion-pair reversed-phase liquid chromatography with diode array UV detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 810: 197-202 [PMID: 15380715 DOI: 10.1016/j.jchromb.2004.07.032]
47. Shen J, Jiao Z, Yu YQ, Zhang M, Zhong MK. Quantification of total and free mycophenolic acid in human plasma by liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 817: 207-213 [PMID: 15686987 DOI: 10.1016/j.jchromb.2004.12.005]
48. Chen B, Gu Z, Chen H, Zhang W, Fen X, Cai W, Fan Q. Establishment of high-performance liquid chromatography and enzyme multiplied immunoassay technology methods for determination of free mycophenolic acid and its application in Chinese liver transplant recipients. Ther Drug Monit 2010; 32: 653-660 [PMID: 20814351 DOI: 10.1097/FTD.0b013e3181f01397]
49. Patel CG, Mendonza AE, Akhlaghi F, Majid O, Trull AK, Lee T, Holt DW. Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 813: 287-294 [PMID: 15556544 DOI: 10.1016/j.jchromb.2004.10.004]
50. Beal JL, Jones CE, Taylor PJ, Tett SE. Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay. Ther Drug Monit 1998; 20: 685-690 [PMID: 9853989 DOI: 10.1097/00007691-199812000-00019]
51. Shipkova M, Schütz E, Armstrong VW, Niedmann PD, Wieland E, Oellerich M. Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. Transplant Proc 1999; 31: 1135-1137 [PMID: 10083508 DOI: 10.1016/S0041-1345(98)01936-8]
52. Hosotsubo H, Takahara S, Imamura R, Kyakuno M, Tanaka T, Yazawa K, Hanafusa T, Matsumiya K, Nonomura N, Okuyama A, Sugimoto H. Analytic validation of the enzyme multiplied immunoassay technique for the determination of mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatographic assay. Ther Drug Monit 2001; 23: 669-674 [PMID: 11802102 DOI: 10.1097/00007691-200112000-00013]
53. van Gelder T, Domke I, Engelmayer J, de Fijter H, Kuypers D, Budde K, Koeger R, Luthe H, Oellerich M. Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. Ther Drug Monit 2009; 31: 218-223 [PMID: 19214147 DOI: 10.1097/FTD.0b013e31819a05f2]
54. Vergara Chozas JM, Sáez-Benito Godino A, Zopeque García N, García Pinteño S, Joumady I, Carrasco García C, Vara Gil F. Analytical validation of a homogeneous immunoassay for determination of mycophenolic acid in human plasma. Transplant Proc 2012; 44: 2669-2672 [PMID: 23146489 DOI: 10.1016/j.transproceed.2012.09.063]
55. Lobritto SJ, Rosenthal P, Bouw R, Leung M, Snell P, Mamelok RD. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. Liver Transpl 2007; 13: 1570-1575 [PMID: 17969194 DOI: 10.1002/lt.21274]
56. Jain A, Venkataramanan R, Kwong T, Mohanka R, Orloff M, Abt P, Kashyap R, Tsoulfas G, Mack C, Williamson M, Batzold P, Bozorgzadeh A. Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. Liver Transpl 2007; 13: 791-796 [PMID: 17538999 DOI: 10.1002/lt.21146]
57. Jain A, Mohanka R, Orloff M, Abt P, Kashyap R, Kelley M, Burlee K, Bozorgzadeh A. Intravenous mycophenolate mofetil with low-dose oral tacrolimus and steroid induction for live donor liver transplantation. Exp Clin Transplant 2005; 3: 361-365 [PMID: 16417444]
58. Jain A, Sharma R, Ryan C, Tsoulfas G, Orloff M, Abt P, Kashyap R, Batzold P, Sauberman L, Safadjou S, Graham M, Bozorgzadeh A. Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction. Liver Transpl 2008; 14: 202-209 [PMID: 18236395 DOI: 10.1002/lt.21348]
59. Shen B, Chen B, Zhang W, Mao H, Shen C, Deng X, Zhan X, Chen H. Comparison of pharmacokinetics of mycophenolic acid and its metabolites between living donor liver transplant recipients and deceased donor liver transplant recipients. Liver Transpl 2009; 15: 1473-1480 [PMID: 19877254 DOI: 10.1002/lt.21895]
60. Pisupati J, Jain A, Burckart G, Hamad I, Zuckerman S, Fung J, Venkataramanan R. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 2005; 45: 34-41 [PMID: 15601803 DOI: 10.1177/0091270004270145]
61. Benichou AS, Blanchet B, Conti F, Hornecker M, Bernard D, Taieb F, Scatton O, Abbas H, Harcouet L, Dauphin A, Calmus Y, Tod M. Variability in free mycophenolic acid exposure in adult liver transplant recipients during the early posttransplantation period. J Clin Pharmacol 2010; 50: 1202-1210 [PMID: 20145258 DOI: 10.1177/0091270009358084]
62. Hwang S, Lee SG, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Choi NK, Kim KW, Yu YD, Park GC, Park PJ, Choi YI. A clinical assessment of mycophenolate drug monitoring after liver transplantation. Clin Transplant 2010; 24: E35-E42 [PMID: 20070319 DOI: 10.1111/j.1399-0012.2009.01166.x]
63. Aw MM, Brown NW, Itsuka T, Gonde CE, Adams JE, Heaton ND, Tredger JM, Mieli-Vergani G, Dhawan A. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. Liver Transpl 2003; 9: 383-388 [PMID: 12682891 DOI: 10.1053/jlts.2003.50022]
64. Hesselink DA, van Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther 2005; 78: 317-321 [PMID: 16198650 DOI: 10.1016/j.clpt.2005.06.008]
65. Jain A, Venkataramanan R, Hamad IS, Zuckerman S, Zhang S, Lever J, Warty VS, Fung JJ. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol 2001; 41: 268-276 [PMID: 11269567 DOI: 10.1177/00912700122010087]
66. Fatela-Cantillo D, Hinojosa-Pérez R, Peralvo-Rodríguez MI, Serrano-Díaz Canedo J, Gómez-Bravo MA. Pharmacokinetic evaluation of mycophenolic acid profiles during the period immediately following an orthotopic liver transplant. Transplant Proc 2006; 38: 2482-2485 [PMID: 17097975 DOI: 10.1016/j.transproceed.2006.08.076]
67. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119-128 [PMID: 11294511 DOI: 10.1097/00007691-200104000-00005]
68. Parker G, Bullingham R, Kamm B, Hale M. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 1996; 36: 332-344 [PMID: 8728347 DOI: 10.1002/j.1552-4604.1996.tb04209.x]
69. Mourad M, Malaise J, Chaib Eddour D, De Meyer M, König J, Schepers R, Squifflet JP, Wallemacq P. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001; 47: 88-94 [PMID: 11148182]
70. Kaplan B, Gruber SA, Nallamathou R, Katz SM, Shaw LM. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation 1998; 65: 1127-1129 [PMID: 9583876 DOI: 10.1097/00007890-199804270-00019]
71. Chen H, Peng C, Yu Z, Shen B, Deng X, Qiu W, Fei Y, Shen C, Zhou G, Yang W, Li H. Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. Clin Pharmacokinet 2007; 46: 175-185 [PMID: 17253887 DOI: 10.2165/00003088-200746020-00005]
72. Hesselink DA, van Hest RM, Mathot RA, Bonthuis F, Weimar W, de Bruin RW, van Gelder T. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resis-tance- associated protein 2. Am J Transplant 2005; 5: 987-994 [PMID: 15816878 DOI: 10.1046/j.1600-6143.2005.00779.x]
73. Brown NW, Aw MM, Mieli-Vergani G, Dhawan A, Tredger JM. Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. Ther Drug Monit 2002; 24: 598-606 [PMID: 12352931 DOI: 10.1097/00007691-200210000-00004]
74. Molina Perez E, Fernández Castroagudín J, Seijo Ríos S, Mera Calviño J, Tomé Martínez de Rituerto S, Otero Antón E, Bustamante Montalvo M, Varo Perez E. Valganciclovir-induced leukopenia in liver transplant recipients: influence of concomitant use of mycophenolate mofetil. Transplant Proc 2009; 41: 1047-1049 [PMID: 19376423 DOI: 10.1016/j.transproceed.2009.02.033]
75. Ting LS, Villeneuve E, Ensom MH. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit 2006; 28: 419-430 [PMID: 16778729 DOI: 10.1097/01.ftd.0000211810.19935.44]
76. Chen H, Gu Z, Chen B, Mao H, Zhang W, Fan Q. Models for the prediction of mycophenolic acid area under the curve using a limited-sampling strategy and an enzyme multiplied immunoassay technique in Chinese patients undergoing liver transplantation. Clin Ther 2008; 30: 2387-2401 [PMID: 19167597 DOI: 10.1016/j.clinthera.2008.12.017]
77. Hao C, Erzheng C, Anwei M, Zhicheng Y, Baiyong S, Xiaxing D, Weixia Z, Chenghong P, Hongwei L. Validation of limited sampling strategy for the estimation of mycophenolic acid exposure in Chinese adult liver transplant recipients. Liver Transpl 2007; 13: 1684-1693 [PMID: 18044788 DOI: 10.1002/lt.21293]
78. Attard TM, Dhawan A, Tredger JM, Conner K, Kling K, Colombani P, Thompson R, Cuffari C. Mycophenolic acid metabolite levels in pediatric liver transplantation: correlation with a limited sampling strategy. J Appl Res 2008; 8: 135-142
79. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 1972; 5: 411-459 [PMID: 4634367 DOI: 10.1016/0010-4809(72)90051-1]
80. David OJ, Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit 2001; 23: 100-114 [PMID: 11294509 DOI: 10.1097/00007691-200104000-00003]
81. van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006; 17: 871-880 [PMID: 16452491 DOI: 10.1681/ASN.2005101070]
82. van Hest RM, van Gelder T, Vulto AG, Mathot RA. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet 2005; 44: 1083-1096 [PMID: 16176120 DOI: 10.2165/00003088-200544100-00006]
83. Shum B, Duffull SB, Taylor PJ, Tett SE. Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol 2003; 56: 188-197 [PMID: 12895192 DOI: 10.1046/j.1365-2125.2003.01863.x]
84. Le Guellec C, Bourgoin H, Büchler M, Le Meur Y, Lebranchu Y, Marquet P, Paintaud G. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet 2004; 43: 253-266 [PMID: 15005639 DOI: 10.2165/00003088-200443040-00004]
85. van der Meer AF, Marcus MA, Touw DJ, Proost JH, Neef C. Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation. Ther Drug Monit 2011; 33: 133-146 [PMID: 21383653]
86. Barau C, Furlan V, Debray D, Taburet AM, Barrail-Tran A. Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children. Br J Clin Pharmacol 2012; 74: 515-524 [PMID: 22329639 DOI: 10.1111/j.1365-2125.2012.04213.x]
87. Saint-Marcoux F, Royer B, Debord J, Larosa F, Legrand F, Deconinck E, Kantelip JP, Marquet P. Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation. Clin Pharmacokinet 2009; 48: 667-675 [PMID: 19743888 DOI: 10.2165/11317140-000000000-00000]
88. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hené RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ. A randomized doubleblind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261-266 [PMID: 10440399 DOI: 10.1097/00007890-199907270-00018]
89. Sarvary E, Nemes B, Varga M, Gaal I, Monostory K, Langer RM, Gorog D, Fazakas J, Kobori L, Fehervari I, Gerlei Z. Significance of mycophenolate monitoring in liver transplant recipients: toward the cut-off level. Transplant Proc 2012; 44: 2157-2161 [PMID: 22974941 DOI: 10.1016/j.transproceed.2012.07.124]
90. Bailey MJ, Dickinson RG. Acyl glucuronide reactivity in perspective: biological consequences. Chem Biol Interact 2003; 145: 117-137 [PMID: 12686489 DOI: 10.1016/S0009-2797(03)00020-6]
91. Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? Transplant Proc 2007; 39: 88-93 [PMID: 17275481 DOI: 10.1016/j.transproceed.2006.10.189]
92. Mardigyan V, Tchervenkov J, Metrakos P, Barkun J, Deschenes M, Cantarovich M. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation. Clin Ther 2005; 27: 463-469 [PMID: 15922819 DOI: 10.1016/j.clinthera.2005.04.004]
93. Kamar N, Marquet P, Gandia P, Muscari F, Lavayssière L, Esposito L, Guitard J, Canivet C, Peron JM, Alric L, Suc B, Saint-Marcoux F, Rostaing L. Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentrationcontrolled doses. Ther Drug Monit 2009; 31: 451-456 [PMID: 19531983 DOI: 10.1097/FTD.0b013e3181aa776e]
94. Beckebaum S, Cicinnati VR, Klein CG, Brokalaki E, Yu Z, Malago M, Frilling A, Gerken G, Broelsch CE. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. Transplant Proc 2004; 36: 2671-2674 [PMID: 15621120 DOI: 10.1016/j.transproceed.2004.10.008]